Menu Search
Equities

OSE Immunotherapeutics SA

0RAD:LSE

OSE Immunotherapeutics SA

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

  • Revenue in EUR (TTM)2.23m
  • Net income in EUR-23.00m
  • Incorporated2004
  • Employees62.00
  • Location
    OSE Immunotherapeutics SA22, boulevard Benoni GoullinNANTES 44200FranceFRA
  • Phone+33 228291010
  • Fax+33 141219107
  • Websitehttps://ose-immuno.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.